A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with TTX-381 for the Ocular Manifestations Associated with Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
This research is looking at a new treatment called TTX-381 for children who have a rare genetic condition called Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 disease). This condition can cause serious eye problems, leading to vision loss. This is the very first time this gene therapy is being given to humans, so it's a very early stage of testing. The main goals are to check if the treatment is safe and if people can tolerate it well over about a year. Doctors will also be closely watching to see if it helps improve or slow down the eye issues associated with CLN2 disease. If successful, this could offer a new way to help children living with this challenging condition.
De un vistazo
¿De qué trata este estudio?
This study is about a new and hopeful treatment for a serious condition called Neuronal Ceroid Lipofuscinosis Type 2, often shortened to CLN2 disease. This is a rare genetic disorder that affects children. Over time, it causes problems with the brain, movement, and sadly, their eyesight. The eye problems can get worse, leading to severe vision loss.
The new treatment being tested is a 'gene therapy' called TTX-381. Gene therapy tries to fix the root cause of certain diseases by introducing healthy genetic material into the body. Think of it like giving the body missing instructions it needs to work properly. In this case, TTX-381 is designed to specifically target the eye and potentially help improve or protect the vision of children with CLN2 disease.
This is a very important step because it's the first time this particular gene therapy is being given to people. This early stage of testing is mainly focused on checking if the treatment is safe and if people tolerate it without too many side effects. Doctors will also be looking closely to see if there are any signs that it is helping with the eye problems caused by CLN2 disease, and how long any effects might last. The hope is that this research could eventually lead to a new treatment option for children who desperately need it.
Puntos clave
- This study is testing a new gene therapy (TTX-381) for eye problems in CLN2 disease.
- It's the first time this treatment is being given to people.
- The main goal is to check for safety and how well people tolerate the treatment.
- Researchers will also look for signs that vision might be improving or stabilising.
- The study lasts about one year, with regular clinic visits.
- This research hopes to find new ways to help children with CLN2.
¿Quién puede ser elegible?
This study is open to both boys and girls who have been diagnosed with Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 disease). There are no specific age limits mentioned, meaning that children of various ages with CLN2 disease could potentially be considered.
To be clear, this study is specifically for individuals with CLN2 disease who are experiencing eye-related issues as a result of their condition. The research team will review each potential participant carefully to make sure the study is a good fit for them.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- I (or my child) have been diagnosed with CLN2 disease.
- I (or my child) am experiencing eye problems linked to CLN2 disease.
- I understand this is a very early stage (first-in-human) study.
- I am willing and able to attend regular clinic appointments for about a year.
¿En qué consiste la participación?
Taking part in this study means you or your child would receive the new gene therapy. You would have regular visits to the clinic for about one year (360 days). During these visits, doctors and nurses would perform various checks. This includes detailed eye exams, blood tests, and possibly collecting samples of tears or spinal fluid (called aqueous humor and CSF) to see how the treatment is working in the body. They would also monitor for any side effects and check your overall health and vision periodically.
Riesgos y beneficios potenciales
Ubicaciones (1)
- —No verificadoAlemania
Preguntas comunes
¿Qué es la terapia génica?
Gene therapy is a medical approach that aims to treat diseases by correcting faulty genes, or by providing new genes, to help the body work correctly.
What is CLN2 disease?
CLN2 disease is a rare, inherited condition that affects the brain and nervous system, leading to problems with movement, speech, and vision, primarily in children.
¿Cuánto tiempo durará el estudio?
The main part of the study where safety and initial effects are checked will last for approximately one year (360 days) after the treatment is given.
Will this treatment cure CLN2 disease?
This early-stage study is primarily focused on safety and seeing if the treatment can help with the eye problems linked to CLN2 disease. It's too early to say if it could be a cure.
What does 'first-in-human' mean?
It means this is the very first time this specific treatment has been given to people, so doctors will be extra careful in checking for safety and how the body reacts.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.